Chau Cheng
Investor Relations Kontakt bei IMMUNOVANT, INC.
Profil
Chau Cheng is currently the Vice President of Investor Relations at Immunovant, Inc. Prior to this, he worked as the Senior Director of Investor Relations at Immunomedics, Inc. from 2004 to 2020.
From 2020 to 2022, he worked as the VP of Investor Relations and Corporate Communications at CytomX Therapeutics, Inc. Dr. Cheng holds a Master's in Business Administration from The Leonard N Stern School of Business.
Aktive Positionen von Chau Cheng
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOVANT, INC. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Chau Cheng
| Unternehmen | Position | Ende |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Investor Relations Kontakt | 01.09.2022 |
| IMMUNOMEDICS, INC. | Investor Relations Kontakt | 01.12.2020 |
Ausbildung von Chau Cheng
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
